Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Inclusion Criteria: Untreated locally advanced cervical cancer patients with clear pathological diagnosis 2019 FIGO stage IIIB-IVA. For patients with stage IIIC disease, the short diameter of their metastatic lymph nodes should ≥1.5cm Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 Life expectancy > 6 months Able to tolerate concurrent chemoradiotherapy assessed by researches No obvious active bleeding; Adequate hematological, renal and hepatic functions: No concomitant malignancies Female subjects of childbearing potential should have a negative pregnancy test and must take effective and reliable contraceptive measures during the clinical trial period; Voluntarily-signed informed consent. Exclusion Criteria: Concomitant other malignancies; Patients with metastatic or recurrent disease; Patients received any form of treatment before enrollment; Severe concomitant chronic diseases (diabetes, hypertension, etc.) or acute infections; Impaired hematological, renal or hepatic functions: Hemoglobin < 9.0 g/dl Neutrophils < 2000 cells/μl; Leukocytes < 4 × 109/L Platelets > 100 × 109/L Serum ALT/AST > 2.5×UNL Serum Total bilirubin > 1.5× UNL g. Serum urea nitrogen (BUN) > 1.5 × upper normal limit (UNL) h. Serum creatinine (Cr) > 1.5 × upper normal limit (UNL) Patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease; Patients with uncontrolled mental diseases; Pregnant or lactating woman; Participating in other clinical trials; Anyone considered not suitable for enrollment by principal investigator;